Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial

Haiming Shi, Jingmin Zhou, Changsheng Ma, Fusui Ji, Yang Wu, Yulan Zhao, Jun Qian, Xiaolong Wang, Haiming Shi, Jingmin Zhou, Changsheng Ma, Fusui Ji, Yang Wu, Yulan Zhao, Jun Qian, Xiaolong Wang

Abstract

Background: A previous phase IV trial revealed sex as a potential effect modifier of MUSKARDIA efficacy in stable coronary artery disease (CAD).

Objective: To assess the clinical effect of MUSKARDIA as a supplemental treatment to optimal medical therapy (OMT) in stable CAD cases.

Methods: This study was a subgroup analysis of a multicenter, randomized, double-blinded, placebo-controlled phase IV clinical study. Eligible individuals underwent randomization to the oral MUSKARDIA and placebo groups and were treated for 24 months. All participants received OMT according to existing guidelines. The primary composite outcome was the major adverse cardiovascular event (MACE), included cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke. The secondary composite outcome encompassed all-cause mortality, non-fatal MI, non-fatal stroke, hospitalization for unstable angina and/or heart failure, and undergoing coronary procedure/surgery during treatment. Safety signals, especially cardiovascular adverse events (AEs), were analyzed.

Results: The female subgroup included 776 participants (384 and 392 in the MUSKARDIA and placebo groups, respectively). The occurrence of the primary composite outcome was lower in the MUSKARDIA group compared with placebo-treated individuals (HR = 0.27, 95%CI: 0.09-0.83; P = 0.02), but the secondary composite outcome showed no significant difference (HR = 0.77, 95%CI: 0.47-1.25; P = 0.29). The MUSKARDIA group had reduced incidence of cardiovascular AEs compared with placebo-treated cases (2.9% vs. 5.6%).

Conclusion: As a supplemental treatment to OMT, 24-month administration of MUSKARDIA is effective and safe in female stable CAD cases.

Clinical trial registration: [https://ichgcp.net/clinical-trials-registry/NCT01897805" title="See in ClinicalTrials.gov">NCT01897805].

Keywords: MUSKARDIA; angina; major adverse cardiovascular event; stable coronary artery disease; women.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Shi, Zhou, Ma, Ji, Wu, Zhao, Qian and Wang.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curve analysis of the primary composite outcome. Hazard ratio = 0.27 (95% confidence interval: 0.09–0.83), P = 0.02.
FIGURE 2
FIGURE 2
Kaplan–Meier curve analysis of the secondary composite outcome. Hazard ratio = 0.77 (95% confidence interval: 0.47–1.25), P = 0.29.

References

    1. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. (2012) 60:e44–164. 10.1161/CIR.0b013e318277d6a0
    1. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology/American heart association task force on practice guidelines, and the American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation. (2014) 130:1749–67. 10.1161/CIR.0000000000000095
    1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. (2013) 168:934–45. 10.1016/j.ijcard.2012.10.046
    1. Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. (2013) 34:2949–3003. 10.1093/eurheartj/eht296
    1. National Institute for Health and Care Excellence. Acute Coronary Syndromes. NICE Guideline [NG185]. London: National Institute for Health and Care Excellence (NICE) (2020).
    1. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. (2015) 385:1397–405. 10.1016/S0140-6736(14)61368-4
    1. Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American college of cardiology foundation. Circulation. (2011) 124:2458–73. 10.1161/CIR.0b013e318235eb4d
    1. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. (2016) 32:1263–82. 10.1016/j.cjca.2016.07.510
    1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. (2016) 37:2315–81. 10.1093/eurheartj/ehw106
    1. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. (2010) 304:1350–7. 10.1001/jama.2010.1322
    1. Lin FJ, Tseng WK, Yin WH, Yeh HI, Chen JW, Wu CC. Residual risk factors to predict major adverse cardiovascular events in atherosclerotic cardiovascular disease patients with and without diabetes mellitus. Sci Rep. (2017) 7:9179. 10.1038/s41598-017-08741-0
    1. De Bacquer D, Dallongeville J, Kotseva K, Cooney MT, Pajak A, Deckers JW, et al. Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories. Int J Cardiol. (2013) 168:910–4. 10.1016/j.ijcard.2012.10.051
    1. Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen. Int J Cardiol. (2013) 165:444–7. 10.1016/j.ijcard.2011.08.080
    1. Fan Y, Feng S, Xia W, Qu L, Li X, Chen S, et al. Aspirin-exacerbated respiratory disease in China: a cohort investigation and literature review. Am J Rhinol Allergy. (2012) 26:e20–2. 10.2500/ajra.2012.26.3738
    1. Xue Y, Feng ZW, Li XY, Hu ZH, Xu Q, Wang Z, et al. The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Acta Pharmacol Sin. (2018) 39:205–12. 10.1038/aps.2017.85
    1. Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol. (2017) 69:2952–66.
    1. Wang J, Lin F, Guo LL, Xiong XJ, Fan X. Cardiovascular disease, mitochondria, and traditional Chinese medicine. Evid Based Complement Alternat Med. (2015) 2015:143145. 10.1155/2015/143145
    1. Zhou Z, Shen W, Yu L, Xu C, Wu Q. A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: a systematic review. J Ethnopharmacol. (2016) 194:1130–9. 10.1016/j.jep.2016.11.024
    1. Fang HY, Zeng HW, Lin LM, Chen X, Shen XN, Fu P, et al. A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases. Sci Rep. (2017) 7:43632. 10.1038/srep43632
    1. Wang S, Peng C, Jiang P, Fu P, Tao J, Han L, et al. Simultaneous determination of seven bufadienolides in rat plasma after oral administration of Shexiang Baoxin Pill by liquid chromatography-electrospray ionization-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. (2014) 967:255–63. 10.1016/j.jchromb.2014.07.038
    1. Chang W, Han L, Huang H, Wen B, Peng C, Lv C, et al. Simultaneous determination of four volatile compounds in rat plasma after oral administration of Shexiang Baoxin Pill (SBP) by HS-SPDE-GC-MS/MS and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. (2014) 963:47–53. 10.1016/j.jchromb.2014.05.047
    1. Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, et al. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial. Chin Med J (Engl). (2020) 134:185–92. 10.1097/CM9.0000000000001257
    1. Zhang KJ, Zhu JZ, Bao XY, Zheng Q, Zheng GQ, Wang Y. Shexiang Baoxin pills for coronary heart disease in animal models: preclinical evidence and promoting angiogenesis mechanism. Front Pharmacol. (2017) 8:404. 10.3389/fphar.2017.00404
    1. Sharma K, Gulati M. Coronary artery disease in women: a 2013 update. Glob Heart. (2013) 8:105–12. 10.1016/j.gheart.2013.02.001
    1. Crea F, Battipaglia I, Andreotti F. Sex differences in mechanisms, presentation and management of ischaemic heart disease. Atherosclerosis. (2015) 241:157–68. 10.1016/j.atherosclerosis.2015.04.802
    1. Davis E, Gorog DA, Rihal C, Prasad A, Srinivasan M. “Mind the gap” acute coronary syndrome in women: a contemporary review of current clinical evidence. Int J Cardiol. (2017) 227:840–9. 10.1016/j.ijcard.2016.10.020
    1. Wada H, Miyauchi K, Daida H. Gender differences in the clinical features and outcomes of patients with coronary artery disease. Expert Rev Cardiovasc Ther. (2019) 17:127–33. 10.1080/14779072.2019.1561277
    1. Perdoncin E, Duvernoy C. Treatment of coronary artery disease in women. Methodist Debakey Cardiovasc J. (2017) 13:201–8. 10.14797/mdcj-13-4-201
    1. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. (2017) 135:1075–92. 10.1161/CIRCULATIONAHA.116.024534
    1. Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. (2012) 33:734–44. 10.1093/eurheartj/ehr331
    1. Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. (2001) 141:735–41. 10.1067/mhj.2001.114198
    1. Ekker MS, de Leeuw FE. Higher incidence of ischemic stroke in young women than in young men: mind the gap. Stroke. (2020) 51:3195–6. 10.1161/STROKEAHA.120.032062
    1. Blomstrand A, Blomstrand C, Ariai N, Bengtsson C, Bjorkelund C. Stroke incidence and association with risk factors in women: a 32-year follow-up of the prospective population study of women in Gothenburg. BMJ Open. (2014) 4:e005173. 10.1136/bmjopen-2014-005173
    1. Hemingway H, Langenberg C, Damant J, Frost C, Pyorala K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation. (2008) 117:1526–36. 10.1161/CIRCULATIONAHA.107.720953
    1. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med. (1994) 120:559–66. 10.7326/0003-4819-120-7-199404010-00005
    1. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, et al. Gender differences in the management and clinical outcome of stable angina. Circulation. (2006) 113:490–8. 10.1161/CIRCULATIONAHA.105.561647
    1. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol. (2003) 55:604–8. 10.1046/j.1365-2125.2003.01795.x
    1. Thomas M, Jones PG, Arnold SV, Spertus JA. Interpretation of the Seattle Angina questionnaire as an outcome measure in clinical trials and clinical care: a review. JAMA Cardiol. (2021) 6:593–9. 10.1001/jamacardio.2020.7478
    1. Liu SH, Chuang WC, Lam W, Jiang Z, Cheng YC. Safety surveillance of traditional Chinese medicine: current and future. Drug Saf. (2015) 38:117–28. 10.1007/s40264-014-0250-z

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir